Moneycontrol

Moneycontrol PRO

HomeNewsSector

Sector

Jump to Category

Focus on new products at pharma companies as generic Revlimid opportunity draws to a close
The current market restrictions that are powering generic Revlimid revenues will end in January 2026
Budget Snapshot: Tight DAP market unlikely to upset government’s fertiliser subsidy calculations
Global DAP market is expected to remain in tight equilibrium in near term amid export curbs by China and production outages
India’s dependence on urea imports reduces, focus should turn to Nano fertilisers
A significant portion of granular fertilisers can be substituted with Nano fertilisers
Muthoot Finance – How long will it shine?
Gold loan demand remains robust aided by RBI diktat on unsecured lending
Advertisement
Remove Ad
Advertisement
Remove Ad
Advertisement
Remove Ad
Advertisement
Remove Ad
Chart of the Day: Renewable energy capacity additions accelerate in 2024
If the industry maintains the current pace of capacity additions, then India can comfortably exceed previous annual highs in renewable energy project installations.
IndusInd Bank Quick Take: MFI loan auction, more pain coming?
While, prima facie, it appears a good move to lighten its bad assets’ burden it is not clear if all the pain has been addressed, given the relatively large microfinance loan book
How pharma companies are fighting back commoditisation of medicine market
The rising usage of generic drugs is undermining pharma market growth in India
Mas Financial – Is the steep correction an opportunity for you?
The stock looks reasonably valued for gradual accumulation from a long-term perspective
Advertisement
Remove Ad
Soft raw material prices to support record profit margins of pharma companies
The falling prices can pose headwinds to API producers but can benefit final drug manufacturers
Chart of the Day: AI initiatives to drive IT spends in 2025
Cost optimisation and productivity improvement objectives are expected to drive IT spends on AI initiatives in 2025
Advent’s rush to scale up Suven Pharma leads it to another acquisition
The NJ Bio acquisition follows Sapala Organics purchase in June
Chart of the Day: India's contract pharma research market to outpace global growth
The higher growth rate will help India gain market share in global pharma outsourcing spends.
Advertisement
Remove Ad
Quick Take: Proposed GST hike on apparel to hurt consumer sentiment
The rate increase could translate into a 5-6 percent rise in mid-to-premium apparel prices.
EaseMy Trip – why this journey may be challenging for investors
Company steadily losing market share and the financial performance reflects the stress

Chart of the Day: Steady capacity additions to help IndiGo maintain leadership in Indian aviation market
Peer Air India group is facing longer delays in aircraft deliveries from Boeing.
Four hits and three misses in Aster DM’s merger with Quality Care
The merger will strengthen Aster’s position in Hyderabad and South India, but it also faces certain challenges.
Advertisement
Remove Ad
There’s a storm coming for the banking industry
Three big sets of draft rules are up in the air for a banking system stymied by low deposits
Chart of the Day: Peak electricity demand growth slows after rising rapidly in FY22-24
The post COVID bump up in demand is showing signs of moderation.
India's pharma market scales new highs despite moderating growth rates
Total sales reached Rs 60,000 crore in the September 2024 quarter
NTPC Green Energy IPO offers a valuable lesson for PSUs in value creation
The IPO values NTPC Green Energy at Rs 91,000 crore to 1 lakh crore, generating value for NTPC investors and setting the to-be-listed company on an independent path
Advertisement
Remove Ad
RateGain Q2 FY25 – good quarter with indications of near-term softness
The company has lowered revenue guidance for the full year as order wins remain sluggish
Chart of the Day: The remarkable recovery in Power Grid’s capex
Total works in hand rose to Rs 1.43 lakh crore in November 2024 from Rs 50,500 crore in the year ago period.
Why India is becoming a hotspot for steel capacity addition
The country’s steady, healthy steel demand growth, preference for domestic capacity, states’ drive for value addition and a healthy balance sheet situation make it an attractive destination
Why investors should back this NBFC amid the overall asset quality stress
The conservative approach to lending with focus on asset quality is a big positive
Advertisement
Remove Ad
Chart of the Day: Q2 cement demand weakest in two years
After subdued Q1 and Q2, hopes now are pinned on recovery in H2 FY25

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347